Metastatic long term responders to ASTX were in CR prior to ASTX. ASTX in 23 high risk breast cancer pts disclosed PFS of 65% at 3 and 52% at 5 years respectively. OS post ASTX was 83% at 3 and 61% at 5 years, respectively . The significance of prognostic factors like age, hormone receptor status, stage at Dg, sites of metastases, response to pretransplant chemotherapy and disease free interval before ASTX will be presented. Conclusion: Subgroup analyses suggest a benefit from ASTX for pts with metastatic breast cancer who achieve CR after conventional chemotherapy. Definition of relevant risk factors will help to better select pts for ASTX. Better detection of minimal residual disease after surgery will particulary help to define the significance of adjuvant therapies. Randomized studies with carefully designed risk profiles should be considered. An integrated proposal for post transplant immunomodulating measures will also be presented.
Donor lymphocyte infusion (DLI) is an effective treatment for patients with chronic myeloid leukemia (CML) in relapse after allogeneic stem cell transplantation (SCT). However, the optimal cell dose for treatment remains to be identified. To address this question we have investigated the factors affecting the cell dose required to achieve remission (effective cell dose, ECD). We analyzed 60 patients treated with escalating doses of donor lymphocytes for CML in relapse after conventional allogeneic SCT. Twenty-one patients were in molecular, 22 in cytogenetic, 17 in hematologic (12 in chronic and 5 in accelerated phase) relapse. Patients transplanted from a sibling (Sib) donor (n=26) received 10e7 -> 5x10e7 -> 10e8 donor CD3+cells/Kg. Patients receiving transplant from a VUD donor (n=34) received 10e6 -> 10e7 -> 5x10e7 -> 10e8 donor CD3+cells/Kg. In order to allow response to each dose to be assessed, the interval between doses was at least 12 weeks (median 22 weeks). Molecular remission was defined by two consecutive negative RT-PCR for BCR-ABL. Failure to respond was defined by the lack of molecular remission one year following the administration of 10e8 CD3+cells/Kg. Fifty-five patients achieved molecular remission (91%). These 55 responder patients were analyzed for the factors affecting the ECD. The ECD was influenced by the disease stage at time of DLI: a dose of 10e6-10e7 was sufficient to restore molecular remission in 64% of patients in molecular or cytogenetic relapse but in only 25% of patients in hematologic relapse (p=0.008). The ECD was also influenced by donor type: 72% of VUD recipients responded to a dose equal or less then 10e7 as compared to 33% of Sib recipients (p=0.001). Five patients (2 Sib and 3 VUD) failed to achieve molecular remission following the administration of 10e8/kg. One patient received 5x10e8 CD3+cells/kg and achieved molecular remission. In the other cases, no cells were available for further treatment. We conclude that the effect of DLI is subject to a dose-response effect, and that ECD correlates with disease stage and donor type. Our findings suggest that, except for those in blastic phase, all CML patients can achieve molecular remission regardless of their disease stage provided a sufficient number of donor lymphocytes is infused.
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Campath-1 antibodies for hematological malignancies: the Cape Town experience N. Novitzky, V. Thomas, G. Hale, H. Waldmann (Observatory, Cape Town, ZA; Oxford, UK) We studied the outcome of 130 consecutive patients with haematological malignancies who received stem cell grafts from HLA identical sibling, depleted of T-cells. The median age was 36 (range 16-59) years, which was significantly older in those receiving PBPC grafts (40, range 16-59; p= 0.002). The diagnosis was AML in CR in 45; ALL in CR in 22, myeloproliferative disorders in 30, multiple myeloma in 11 and 22 had lymphoproliferative disorders. Myeloablative conditioning was with fractionated (f) total body irradiation (12 GY), f total nodal irradiation (6 GY) and cyclophosphamide (120 mg/kg). 11 patients received busulfan (12 mg/kg), melphalan (100-140 mg/m²) and thiotepa (500 mg/m²). The source of haematopoieitic stem cells was bone marrow in 62 and cytokine mobilised progenitor cells (PBPC) in 68. GVHD prophylaxis was by ex vivo (''in the bag'') incubation of the stem cell concentrates with CAMPATH-1 G (N= 76) and H (humanised; N= 54) antibodies. No patient receiving BMT was given post transplant GvHD prophylaxis. Ten patients who had received PBPC grafts were given prophylaxis with prednisone 30 mg daily, while another 30 received cyclosporin for 90 days. In patients receiving BMT the mononuclear marrow cell dose infused was 0.78 x 10^8/kg, containing 9.9 x 10^4/kg CFU-GM. Patients transplanted with PBPC grafts received a median of 8.71 x 10^8/kg mononuclear cells containing 2.32 x 10^6/kg CD34+ cells and 22.5 (5-390; p= 0.04) x 10^4/kg CFU-GM. The median dose of anti CD52 antibodies was 20 mg (5-45). Compared to BMT recipient, patients transplanted with PBPC recovered the leukocyte and platelet counts faster (median 12 days; p= 0.02). Acute GVHD was detected in 6 recipients of BM and 9 of PBPC transplants. Chronic GvHD was not seen in the former group but developed in 8 of the latter (p= 0.005). While GVHD was well controlled with corticosteroids, it was associated with higher mortality from opportunistic infections. Patients with CML had a high disease recurrence rate (72%), but except one, all responded to escalading dose DLI, leading to 62% surviving disease free. Median follow up for all patients is 1055 (range 28-4867) days. Death occurred at a median of 188 days (range 16-57) in 34% receiving a BMT and 40% PBPC and it was due to relapse in 16 and 9 (p= 0.03; x² test) patients respectively. There was no significant difference in the survival between patients who received BMT of PBPC, or between patients receiving PBPC treated with the two antibodies. Survival was best in those who were given less than and equal to 20mg CAMPATH-1 (p= 0.01), particularly in the subgroup who received CAMPATH-1H and post transplantation cyclosporin as 75% survive disease free at a median of 618 (22-1705) days. Cox analysis showed that survival was associated with absence of GVHD and treatment with CAMPATH-1 H antibodies supplemented with cyclosporin.
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Adult haplo-identical transplants: hazards and benefits of GM-CSF post-transplant plus a single DLI at day 28 P. Lewalle, I. Ahmad, A. Triffet, A. Delforge, P. Crombez, D. Bron, P. Martiat (Bruxelles, B) Haplo-identical transplant is now a procedure of choice for patients who lack a compatible donor. However, they are still referred heavily pre-treated, at very advanced stages. This results in high risks of relapse and infections. We started a twostep study to improve both relapse rate and immunity (second step: replacement of G -CSF by GM-CSF post-transplant). Twenty consecutive leukemia/lymphoma (FL) patients were investigated (primary refract: 4, refract rel: 8, CML 2nd CP progressive on STI: 2, early rel in PR: 4 and CR: 2). GvH type NK alloreactivity was chosen when possible (10/20). The graft was T and B-cell depleted with a fixed reinfused CD3 dose of 5x104/kg. All but one patients engrafted before day 20. In the first 8 patients, G-CSF was given from day 5. Prophylactic DLI started at month 1 (3x104 CD3/kg) in the 2 first patients. This resulted in grade II aGVHD and cGVHD in both. We gave next 1x104/kg monthly for 3 consecutive months. This was well tolerated with only one grade I GVHD. Overall, 5 patients relapsed rapidly (before month 6) and were given therapeutic DLI, starting at 1x105 CD3/kg with escalation every 2 weeks if no GVHD. This led to CR in 1/5. We next gave monthly escalated (1, 3 and 10x104) doses. This produced aGVHD grade 2-3 in all. Thus G-CSF from day 5 and monthly DLI (1x104 CD3/kg) are safe. They results in faster CD4 recovery and a low rate of infections. However, in refractory diseases, this remains insufficient to induce a protective GVL effect. Therapeutic DLI can be given at higher doses, depending on the timing. In the next 12 patients, GM-CSF was used first from day 1 plus monthly DLI (grade II GVHD in 2 patients), next from day 5 plus a single DLI. This produced either no or Grade I GVHD. TRM was 2/17 at day 100, 3/17 at one year (infectious complication of GVHD) and 5/17 in total (CR patients with late exacerbation of cGVHD). RRM occurred in 7 patients and 8 patients are alive in CR (3 patients are too early to be evaluated but will be presented). In GM-CSF patients, the mean CD4 count was 183 at day 56. In patients developing any grade of aGVHD, relapse rate was 3/9 suggesting a protective effect. However, the price to pay is high for GVHD greater than I (3 deaths). We thus aim at a scheme producing no or grade I GVHD. We conclude that DLI are feasible in these patients, that GM-CSF plus one DLI tends to produce more GVHD, mainly grade I when given from day 5, and that even grade I GVHD could be protective.
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Mesenchymal stem cell inhibitory effect on T-cell responses is mediated by non-cognate physical interaction S. Glennie, M. Krampera, P. Dyson, D. Scott, R. Laylor, E. Simpson, F. Dazzi (London, UK) Mesenchymal stem cells (MSC) are cells of stromal origin characterized by the ability to differentiate, into various types of tissues. MSC interact with hematopoietic stem cells and influence their homing and differentiation. Furthermore, they inhibit T -cell proliferation to mitogens and in polyclonal, polyepitope MLR. We have recently shown that MSC inhibit response of naïve and memory T cells to cognate antigenic epitopes. However, the mechanisms underlying MSC immunoregulatory activity are entirely unknown. We characterized the MSC inhibitory effect on the immune response to murine male transplantation antigens, HY. Female mice immunized with male cells or mice transgenic for HY-specific Tcell receptor were stimulated in vitro with HY peptides in the presence or absence of MSC. In this system MSC inhibit HYspecific T cells in a dose-dependent fashion and affect cell proliferation, cytotoxicity, and the number of IFNg producing HY peptide-specific T cells. We observed that the inhibitory effect is already detectable at 24 hours but it is relieved once MSC are removed from the culture. These results suggest that MSC transiently suppress T-cell responses without inducing tolerance. To investigate whether MSC specifically inhibit the T cells which became activated after encountering antigen, we reduced the ratio between antigen-specific and non-antigen-specific T cells in the responder cell population of up to 10 fold. No difference in the magnitude of inhibition was observed, thus implying that MSC inhibitory effect did not selectively target antigen-reactive T cells. The depletion of CD4+/CD25+ regulatory T cells from the responder population and the replacement of antigen-pulsed antigen presenting cells (APC) with CD3/CD28 coated beads did not modify the inhibitory effect. To assess whether T -cell suppression was mediated directly by soluble factors, MSC were separated from responder T cells using a Transwell system or MSC were replaced by MSC culture supernatant. In both cases the inhibitory activity was abrogated. The MSC effect was not inhibited by the addition of anti-TGFb blocking antibodies and no IL-10 was detected in MSC culture supernatants. We conclude that MSC physically hinder T cells from the contact with APC in a non-cognate fashion. We surmise that such an effect may not be confined to the immune system but have a more general inhibitory activity on the cell cycle in a variety of cell types.
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Transplantation of highly purified peripheral blood CD34+ cells from sibling donors without prophylactic posttransplant immunosuppression in first chronic phase chronic myeloid leukemia: results of an extended phase II study D.W. Beelen, A.H. Elmaagacli, H. Ottinger, R. Trenschel, N. Steckel, R. Peceny (Essen, D) An extended phase-II-study of transplantation using rhG-CSFmobilized highly purified peripheral blood CD34+ cells from HLAidentical sibling donors without prophylactic posttransplant immunosuppression is being performed since 09/98 in adult patients (pts) with first chronic phase chronic myeloid leukemia (CML) (Beelen et al. Bone Marrow Transplant 26: 823-829, 2000) . To date, a total of 49 pts (median age 39 yrs, median pretransplant risk score 2) have been included in this phase-IIstudy. CD34+ cells were purified by large-scale magneticactivated cell separation using the Clinimacs (TM) device (Miltenyi Biotec, Bergisch Gladbach, Germany). Grafts contained a median of 9.7 (1.7 -16.6) x 10e6 CD34+ cells/kg of recipient b.w. with a purity between 94.5% and 98.3% (median 97.2%) and a median of 6 (1 -85) x 10e3 CD3(+) T cells/kg, corresponding to a T cell depletion efficacy of log 4.8. Myeloablative conditioning consisted of fractionated total body irradiation (4 x 2.5 Gy), 10 mg/kg thiotepa, 120 mg/kg cyclophosphamide, and 4 x 10 mg/kg antithymocyte globuline. Escalating-dose donor lymphocyte infusions (DLI) were incorporated after the first 17 pts and were highly effective in inducing molecular remissions in pts with residual bcr/abl transcripts. The overall estimate of grades I-IV acute GvHD is 20% (grades I: 12%, II: 4%, III-IV: 4%) and the 4 yrs-estimate of chronic GvHD is 26% (extensive chronic GvHD 9%). Three pts (6%) developed a hematologic relapse which converted to molecular remission in 2 pts after DLI. After a median follow-up of 20 months, 48 pts (98%) are currently alive (4 yrs-survival estimate 93%). One patient aged 59 yrs died from metastatic prostatic cancer at 27 months posttransplant. The relative prevalence of being in molecular/cytogenetic remission is 65%/94% at 2 yrs and 88%/100% at 3 yrs, respectively. In conclusion, this extended phase-II-study demonstrates that transplantation of highly purified peripheral blood CD34+ cells from HLA-identical sibling donors in chronic phase CML patients is safe, effectively prevents acute GvHD, and is capable to induce durable molecular and cytogenetic remissions, if combined with posttransplant DLI. This transplant approach is associated with a particularly low transplant-related morbidity and mortality after HLA-identical sibling transplants and should therefore be prospectively compared to the standard immunoprophylaxis of acute GvHD in this setting.
O283 Preparation of mesenchymal stem cells for therapy of neurometabolic diseases in pediatric patients
I. Mueller, T. Leimig, D. A. Persons, D. Niethammer, R. Handgretinger (Tuebingen, D; Memphis, USA) Bone marrow aspirates give rise to a heterogeneous population of adherent cells in plastic culture vessels. During long-term culture the dominant portion of cells display fibroblast-like morphology and express the surface markers CD105 and CD73.
This population has been shown to contain pluripotent stem cells, referred to as mesenchymal stem cells (MSC). Recent experiments, however, have shown that the plasticity of these cells extends beyond mesenchymal tissue. Cells of all three germinal layers have been successfully derived from these cells. We assessed the generation of MSC from bone marrow aspirates and optimised cell culture conditions under GMP conditions. We found that yield and proliferative capacity varied significantly from donor to donor. Furthermore, the culture in a closed system of culture bags was tested. Here, introduction of cells and exchange of media is facilitated by adapters for syringes, reducing risk of contamination significantly. For use in gene therapeutic approaches we developed an efficient system for retroviral transduction using GFP as marker protein. We used a MSCV-derived vector produced under GMPconditions, which contains the GFP gene under control of a CMV promoter. GFP-transduced human MSC were transplanted into the immunedeficient RAG-/-mouse strain to analyse engraftment and differentiation pattern. Potential future applications of this system include numerous inborn errors of metabolism. In particular, it has been speculated that the combined transplantation of bone marrow and ex vivo expanded MSC might be superior to bone marrow transplantation alone for neurometabolic diseases in children. This programme is being initiated and eligibility criteria are being established.
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The immature laminin-receptor protein is a suitable target for immunotherapy against hematological malignancies M. Zeis, S. Siegel, A. Wagner, N. Schmitz (Hamburg, D) The immature Laminin-Receptor protein (iLRP) is a highly conserved protein which is preferentially expressed in fetal tissues and in many types of cancer including hematopoietic malignancies whereas iLRP is not detectable on normal differentiated adult cells.To investigate whether iLRP-specific cytotoxic T lymphocytes (CTL) are capable of killing iLRPexpriming hematological targets, CTL were generated from healthy HLA-A*0201 positive volunteers by incubating T cells with autologous dendritic cells (DCs) transfected with iLR-RNA. Results: ILRP-specific CTL lysed HLA-A2+ iLRP+ tumor cells including several lymphoma and leukemia cell lines, as well as fresh leukemic blasts from AML patients, indicating that iLRPderived peptides are naturally processed and presented by tumors. Normal iLRP-negative target cells (CD14+ monocytes, activated B cells) were not attacked by iLRP-specific CTL. In a next step, the therapeutic efficacy of iLR-RNA transfected DCs against a murine B-cell lymphoma model (A20) was evaluated. Balb/c mice received three s.c. vaccinations of 5 x 105 iLR-RNADCs followed by an inoculation of 105 A20 lymphoma cells (s.c.). As a result, 80% of the treated animals were able to completely reject the tumor.For the first time, these data show that the immature laminin receptor protein can be used as a target for specific immunotherapeutic strategies against hematological malignancies.
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Ex vivo generation of cytotoxic T-cells, specific for the hematopoietic system restricted minor histocompatibility antigen HA-1/H
